Sign in
Not yet taking people in United StatesPhase 3

Adds iSCIB1+ vaccine to standard immunotherapy for advanced melanoma

Tests adding iSCIB1+ vaccine to ipilimumab and nivolumab in advanced melanoma.

Key facts

Who runs it
Scancell Ltd
Where
Aurora, United StatesSee the siteAlso in 1 other country, 1 site
Trial code
Registry title
iSCIB1+ in Combination With Ipilimumab and Nivolumab as First-Line Treatment for Advanced Unresectable Melanoma
Status
Not yet recruiting
Phase
Phase 3
People taking part
550 people, planned
Starts
1 Dec 2026
Expected to end
1 Dec 2032
Type of study
Interventional, 2 groupsOne group gets a placebo (a dummy treatment), for comparison.
Treatments tested
  • iSCIB1+
  • Nivolumab & Ipilimumab
  • Placebo
Record updated
11 September 2026

Who can take part

AI summary

From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.

The trial is looking for adults with melanoma that has spread or cannot be removed by surgery, who have not yet had anti-PD1 treatment for it. They get a DNA cancer vaccine (iSCIB1+) or a placebo, plus nivolumab and ipilimumab.

Age
18 years or older
Sex
All sexes can join.
Disease stage
Stage III or Stage IV melanoma that cannot be removed by surgery. Melanoma of unknown primary is allowed. At least one lesion that can be measured on a CT scan or MRI. Life expectancy of more than 6 months. ECOG performance status of 0 or 1.
Earlier treatment
No earlier anti-PD1 treatment for advanced disease. No adjuvant treatment within 6 weeks of Day 1. No investigational product within 28 days. No systemic steroids or other immune-suppressing medicine above physiological dosing within 7 days of Day 1.
Biomarker or test result
Positive for at least one of these HLA types: A2, A3, A31, Bw4, B44 and B35. BRAF status must be known.

Main reasons for not taking part

  • Mucosal, ocular or acral melanoma
  • Symptomatic brain metastases or carcinomatous meningitis
  • Active autoimmune disease or a history of it that needs systemic steroids or immune-suppressing medicine
  • HIV-1/2 infection, or active hepatitis B or C infection
  • Solid organ transplant, or breastfeeding during treatment

The registry criteria, word for word

Show all 31 criteriaShow less

Other criteria

  • 5.1.Inclusion Criteria
  • Participant has histologically confirmed, unresectable Stage III or Stage IV melanoma as defined by the AJCC (Gershenwald et al., 2017). Participants with a diagnosis of melanoma of unknown primary are eligible
  • Participant is positive for at least one of the following HLA alleles: HLA- with an HLA type of any one of HLA MHC class I: A2, A3, A31, Bw4, B44 and B35
  • Participant has been clinically evaluated, and checkpoint inhibition has been determined to be an appropriate treatment for their advanced disease
  • Participant's BRAF status must be known; participants with BRAF mutation positive disease may be enrolled without BRAF-inhibitor treatment at the discretion of the Study Investigator
  • Participant has at least one measurable lesion per RECIST 1.1 criteria by computed tomography CT scan or MRI
  • Participant is at least 18 years of age
  • Participant has a life expectancy of more than 6 months
  • Participant has an ECOG performance status of 0 or 1
  • Participant has adequate organ function as determined by the following laboratory values:; Absolute neutrophil count ≥ 1.5 x 109/L Lymphocyte count ≥0.5 x 109/L Platelet count ≥100 x 109/L Hemoglobin >9 g/dL (> 5.6 mmol/L) Serum creatinine or creatinine clearance ≤1.5x ULN >50 mL/min Serum total bilirubin ≤1.5 x ULN or <3.0 mg/dL if participant has Gilbert's syndrome Serum transaminases, AST and ALT ≤2.5 x ULN or ≤5.0 x ULN if liver metastases present
  • Participant must be able and willing to provide written IRB/REC-approved informed consent prior to any study-related procedure
  • Women of childbearing potential must agree to use highly effective contraceptive methods prior to study entry, for the whole duration of study treatment, and for at least 5 months following the last dose or in accordance with the SmPC of the IC SOC CPI (whichever is most conservative); See Appendix D: Guidance on Acceptable Contraceptive Methods for full guidance
  • Women of childbearing potential must have a negative serum pregnancy test at screening and within two days before IMP (or placebo) administration
  • Participant must be willing and able to comply with scheduled visits, treatment plan, laboratory tests and other study procedures; 5.2.Exclusion Criteria
  • Participant has a diagnosis of mucosal, ocular or acral melanoma
  • Participant has received prior systemic anti-PD1 treatment for advanced disease
  • Participant has received prior adjuvant treatment, defined as treatment following resection of all detectable disease, within 6 weeks of Day 1 (first dose of IMP)
  • Participant has BRAF mutation positive disease with evidence of rapid PD
  • Participant has symptomatic brain metastases or carcinomatous meningitis. Symptomatic brain metastases are defined as brain metastases causing neurological signs or symptoms attributable to intracranial disease and/or requiring corticosteroid therapy for the management of brain metastasis-related symptoms. Participant is expected to require and elect any other form of systemic or localized anticancer therapy while receiving study treatment
  • Participants receive treatment with any investigational product within 28 days (or five half-lives of the treatment concerned if longer than 28 days) prior to Day 1
  • Participant has had a previous or current malignancy within 5 years, with the exception of melanoma and curatively treated local tumors
  • Participant has a concurrent illness/diagnosis which are uncontrolled and/or would preclude study conduct and assessment
  • Participant has NYHA class III or IV heart disease
  • Participant has a history of severe hypersensitivity reaction to treatment with a mAb
  • Participant has an active autoimmune disease or a documented history of autoimmune disease or syndrome that requires systemic steroids or immunosuppressive agents above physiological dosing
  • Received a live vaccine or non-live vaccine (including COVID-19 vaccines) within 7 days prior to first dose of study treatment
  • Participant has received systemic steroids or is receiving any other form of immune suppressant medication above physiological dosing within 7 days of Day 1
  • Participant is positive for HIV-1/2 infection or is positive for HBsAg or HCV antigen consistent with active infection
  • Participant has a known current or recent history (within the last year) of substance abuse including illicit drugs or alcohol to the extent where it would negatively affect compliance with the trial protocol based on Study Investigator's decision
  • Participant has received a solid organ transplant
  • Participant is breastfeeding during the study treatment phase, and for at least five months following the last dose or in accordance with the SmPC of I/N (whichever is most conservative)

Where in United States

Also in 1 other country, 1 site

  • University of Colorado Cancer CenterAurora, United StatesContact: Sapna Patel (principal investigator)Not yet recruiting

About the trial

What the trial wants to find out

This Phase 3 clinical trial is evaluating whether adding iSCIB1+, an investigational DNA-based cancer vaccine, to standard immunotherapy with nivolumab and ipilimumab can improve outcomes for people with advanced unresectable melanoma.

Read full original descriptionShow less

Participants will be randomly assigned to receive either iSCIB1+ or a placebo, in addition to standard treatment with nivolumab and ipilimumab. Neither participants nor study doctors will know which treatment has been assigned. The study will compare how long participants live without their cancer worsening, overall survival, tumor response, safety, and quality of life.

iSCIB1+ is designed to stimulate the immune system to recognize and attack melanoma cells by targeting proteins commonly found on melanoma tumors. Earlier studies have shown encouraging signs of immune activation and anti-tumor activity when iSCIB1+ was combined with checkpoint inhibitor immunotherapy. This study aims to determine whether adding iSCIB1+ to standard immunotherapy provides additional benefit compared with standard immunotherapy alone

The 2 groups in the trial

  • iSCIB1+ in combination with Ipilimumab and NivolumabTreatment being tested

    Participants will receive iSCIB1+ in combination with standard immunotherapy consisting of nivolumab and ipilimumab. Treatment will be administered according to the protocol-defined dosing schedule. Following induction treatment with nivolumab and ipilimumab, participants will continue nivolumab maintenance therapy. This arm is designed to evaluate whether the addition of iSCIB1+ improves clinical outcomes compared with placebo when administered in combination with nivolumab and ipilimumab in participants with advanced unresectable melanoma.

    Treatment: iSCIB1+ and Nivolumab & Ipilimumab

  • Placebo + Nivolumab and IpilimumabPlacebo, for comparison

    Participants will receive placebo in combination with standard immunotherapy consisting of nivolumab and ipilimumab. Treatment will be administered according to the protocol-defined dosing schedule. Following induction treatment with nivolumab and ipilimumab, participants will continue nivolumab maintenance therapy. This arm serves as the comparator for evaluating the efficacy and safety of iSCIB1+ when added to standard first-line immunotherapy in participants with advanced unresectable melanoma.

    Treatment: Nivolumab & Ipilimumab and Placebo

Questions to ask the study team

  1. How often do I need to come in, and for how long each time?
  2. Are travel costs paid?
  3. Can I keep my own doctor?
  4. What happens if I want to stop?

Contact the study team: see the registry record → Contacts and Locations

Print a page for my doctor

Data and sources

Registry record
Listed on ClinicalTrials.gov.
Official title
A Phase 3 Multicenter, Randomized, Double-Blind, Placebo-Controlled, Adaptive Study of iSCIB1+ in Combination With Ipilimumab and Nivolumab as First-Line Treatment for Advanced Unresectable Melanoma
Plain-language title
Adds iSCIB1+ vaccine to standard immunotherapy for advanced melanomaGenerated from the registry record. The registry title is the official one.
AI summary
From the trial's eligibility criteria. Read by machine on 12 November 2026.
Record updated
11 September 2026